Search Results - "Dezzani, Luca"

Mutations in the 5′ UTR of ANKRD26, the Ankirin Repeat Domain 26 Gene, Cause an Autosomal-Dominant Form of Inherited Thrombocytopenia, THC2 by Pippucci, Tommaso, Savoia, Anna, Perrotta, Silverio, Pujol-Moix, Núria, Noris, Patrizia, Castegnaro, Giovanni, Pecci, Alessandro, Gnan, Chiara, Punzo, Francesca, Marconi, Caterina, Gherardi, Samuele, Loffredo, Giuseppe, De Rocco, Daniela, Scianguetta, Saverio, Barozzi, Serena, Magini, Pamela, Bozzi, Valeria, Dezzani, Luca, Di Stazio, Mariateresa, Ferraro, Marcella, Perini, Giovanni, Seri, Marco, Balduini, Carlo L.

“…THC2, an autosomal-dominant thrombocytopenia described so far in only two families, has been ascribed to mutations in MASTL or ACBD5. Here, we show that…”
Get full text

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses by Cesne, Axel Le, Bauer, Sebastian, Demetri, George D, Han, Guangyang, Dezzani, Luca, Ahmad, Qasim, Blay, Jean-Yves, Judson, Ian, Schöffski, Patrick, Aglietta, Massimo, Hohenberger, Peter, Gelderblom, Hans

“…PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup…”
Get full text

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis by Yang, Lin, Alyasova, Anna, Ye, Dingwei, Ridolfi, Antonia, Dezzani, Luca, Motzer, Robert J

“…RECORD-4 assessed everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after 1 prior anti-vascular endothelial growth factor…”
Get full text

Cell fusion in tumor progression: the isolation of cell fusion products by physical methods by Pedrazzoli, Filippo, Chrysantzas, Iraklis, Dezzani, Luca, Rosti, Vittorio, Vincitorio, Massimo, Sitar, Giammaria

“…Cell fusion induced by polyethylene glycol (PEG) is an efficient but poorly controlled procedure for obtaining somatic cell hybrids used in gene mapping,…”
Get full text

The impact of large oncology meetings (#ASCO, #AACR, #ASH) and health equity hashtags (#DEI+) on social media engagement by Dizon, Don S., Florez, Narjust, Subbiah, Vivek, Weeks, Lachelle Dawn, Dezzani, Luca, Juneja, Renu, Smith, John, Edobor, Wanda

“…e23008 Background: Social media has revolutionized scientific communication to extend engagement beyond peer-reviewed publications and traditional media…”
Get full text

Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ by Bjarnason, Georg A., Kollmannsberger, Christian K., Ahmad, Qasim, Dezzani, Luca, Elmeliegy, Mohamed, Han, Jackie, Nathan, Paul D.

“…Abstract only 4574 Background: COMPARZ was a randomized, controlled, open-label, phase 3 trial that demonstrated comparable efficacy of first-line PAZ and SUN,…”
Get full text

Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study) by de Souza, Paul L., Wong, Shirley, Sewak, Sanjeev, Kotasek, Dusan, Keam, Bhumsuk, Chung, Jinsoo, Erbeck, Noelle, Han, Jackie, Dezzani, Luca, Ahmad, Qasim, Mainwaring, Paul N.

“…Abstract only 648 Background: EVE following failure of sorafenib or sunitinib for RCC was first approved by the FDA in 2009. CATChEz (NCT01545817) was designed…”
Get full text

Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis by Tannir, Nizar M., Porta, Camillo, Gruenwald, Viktor, Choueiri, Toni K., Ahmad, Qasim, Carrasco Alfonso, Marlene, Dezzani, Luca, Han, Jackie, Sternberg, Cora N.

“…Abstract only 4572 Background: COMPARZ (NCT00720941) was a phase 3, randomized, controlled, open-label trial that demonstrated comparable efficacy of…”
Get full text

Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL study) by Schmidinger, Manuela, Procopio, Giuseppe, Hawkins, Robert E., Rodriguez Sanchez, Angel, Vazquez, Sergio, Srihari, Narayanan, Kalofonos, Haralabos, Bamias, Aristotelis, Bono, Petri, Babanrao Pisal, Chaitali, Hirschberg, Yulia, Dezzani, Luca, Ahmad, Qasim Iftikhar, Jonasch, Eric

“…Abstract only…”
Get full text

Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma by Jonasch, Eric, Procopio, Giuseppe, Hawkins, Robert E., Rodriguez Sanchez, Angel, Vazquez, Sergio, Srihari, Narayanan, Kalofonos, Haralabos, Bamias, Aristotelis, Bono, Petri, Babanrao Pisal, Chaitali, Hirschberg, Yulia, Dezzani, Luca, Ahmad, Qasim Iftikhar, Schmidinger, Manuela

“…Abstract only…”
Get full text

Development of a prognostic nomogram for liver toxicity in patients treated with pazopanib by Kattan, Michael W., Van Der Graaf, Winette T.A., Powles, Thomas, Lam, Simon, Ahmad, Qasim, Dezzani, Luca, Han, Jackie, Sternberg, Cora N.

“…Abstract only 455 Background: Potential liver toxicity associated with pazopanib treatment has provided a challenge for decision-making regarding patient…”
Get full text

Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America by Queiroz Muniz, David, Ratto, Barbara, Yang, Hongbo, Zhao, Jing, Jenkins, Madeline, Signorovitch, James, Dezzani, Luca, Salman, Pamela, Lema Medina, Mauricio, Lopera, Diego, Lerzo, Guillermo, del Castillo, Cesar, Chacon, Matias, Martin, Ana, Campos-Gomez, Saul

“…Introduction Pazopanib is approved in Latin America as first targeted therapy for patients with metastatic renal cell carcinoma (mRCC). Methods A retrospective…”
Get full text

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma by Sternberg, Cora N., Motzer, Robert J., Hutson, Thomas E., Choueiri, Toni K., Kollmannsberger, Christian, Bjarnason, Georg A., Paul Nathan, Porta, Camillo, Grünwald, Viktor, Dezzani, Luca, Han, Jackie, Tannir, Nizar M.

“…The phase III COMPARZ study showed noninferior efficacy of pazopanib versus sunitinib in advanced renal cell carcinoma. In this COMPARZ post hoc analysis we…”
Get full text

Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma by Procopio, Giuseppe, Bamias, Aristotelis, Schmidinger, Manuela, Hawkins, Robert, Sánchez, Angel Rodriguez, Estevez, Sergio Vázquez, Srihari, Narayanan, Kalofonos, Haralabos, Bono, Petri, Pisal, Chaitali Babanrao, Hirschberg, Yulia, Dezzani, Luca, Ahmad, Qasim, Rodriguez, Cristina Suárez, Jonasch, Eric

“…The objective of this study was to determine the effectiveness and safety of pazopanib in patients with intermediate-risk advanced/metastatic renal cell…”
Get full text

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis by Hochhaus, Andreas, Mahon, Francois-Xavier, Coutre, Philipp le, Coriu, Daniel, Petrov, Ljubomir, Ossenkoppele, Gert J., Cross, Nicholas C.P., Müller, Martin C., Rea, Delphine, Steegmann, Juan Luis, Castagnetti, Fausto, Hellmann, Andrzej, Rosti, Gianantonio, Gattermann, Norbert, Coronel, Maria Liz Paciello, Gutierrez, Jose Valentin Garcia, Tubazio, Viviana, Pellegrino, Angela, Dezzani, Luca, Giles, Francis J.

“…▪ Background: The cytogenetic hallmark of chronic myeloid leukemia (CML) is a translocation, t(9;22)(q34;q11), resulting in the Philadelphia (Ph) or derivative…”
Get full text

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase by Rea, Delphine, Rosti, Gianantonio, Cross, Nicholas C.P., Hellman, Andrzej, Niederwieser, Dietger, Pungolino, Ester, Falzetti, Franca, Pregno, Patrizia, Orlandi, Ester Maria, Almeida, Antonio Medina, Illes, Arpad, Fernandez, Cristalina, Dezzani, Luca, Pellegrino, Angela, Costantini, Chiara, Walasek, Claudia, Saglio, Giuseppe, Steegmann, Juan Luis, Baccarani, Michele

“…Background Tyrosine kinase inhibitors (TKIs) are the standard of care for pts with CP-CML. Current recommendation is to continue TKI therapy indefinitely but…”
Get full text

Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis by Giles, Francis J., Rea, Delphine, Baccarani, Michele, Cross, Nicholas C.P., Steegmann, Juan Luis, Griskevicius, Laimonas, Coutre, Philipp le, Coriu, Daniel, Petrov, Ljubomir, Ossenkoppele, Gert J., Mahon, Francois-Xavier, Müller, Martin C., Hellmann, Andrzej, Porkka, Kimmo, Brümmendorf, Timothy H., Gastl, Gunther, Tubazio, Viviana, Pellegrino, Angela, Dezzani, Luca, Rosti, Gianantonio, Hochhaus, Andreas

“…▪ Background: The incidence of CML increases with age and also the disease characteristics vary with age. However, whether age has any impact on molecular…”
Get full text

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis by Hochhaus, Andreas, Mahon, Franҫois-Xavier, le Coutre, Philipp, Petrov, Ljubomir, Janssen, Jeroen J. W. M., Cross, Nicholas C. P., Rea, Delphine, Castagnetti, Fausto, Hellmann, Andrzej, Rosti, Gianantonio, Gattermann, Norbert, Coronel, Maria Liz Paciello, Gutierrez, Maria Asuncion Echeveste, Garcia-Gutierrez, Valentin, Vincenzi, Beatrice, Dezzani, Luca, Giles, Francis J.

“…Purpose The ENEST1st sub-analysis presents data based on Philadelphia chromosome (Ph) status, i.e., Ph+ and Ph−/ BCR-ABL1  + chronic myeloid leukemia. Methods…”
Get full text

Thrombopoietin (TPO) Levels in Inflammatory Disorders with or without Reactive Thrombocytosis by Noris, Patrizia, Ceresa, Iride F., Ambaglio, Chiara, Dezzani, Luca M., Balduini, Carlo L.

“…TPO, the primary regulator of megakaryopoiesis, is produced at a constant rate and is removed from the circulation by adsorption to specific receptors on…”
Get full text

Italy by Andrioli, Simonetta, Dezzani, Luca

“…Since the introduction of securitization in Italy in the mid 1990s, and the passage on April 30, 1999, of Law 130 on securitization, the Italian securitization…”
Get full text